Anti-Pseudomonas Activity of KaloBios'/sanofi pasteur's KB001 May Prevent Serious Lung Infections and Limit Damaging Inflammation - May 17, 2010
KaloBios Partners with Sanofi Pasteur on Novel Prevention and Treatment for Pseudomonas aeruginosa - January 11, 2010
KaloBios' KB001 Antibody Shows Encouraging Safety and Activity in New Approach to Fighting Pseudomonas Infection in Cystic Fibrosis Patients - October 15, 2009
KaloBios Raises Additional $12 Million in Series D Venture Financing for a New Total of $32 Million - December 22, 2008
KaloBios Raises $20 Million in Series D Venture Financing - September 23, 2008
KaloBios Initiates Phase 1/2 Trial of Humaneered� Monoclonal Antibody KB001 for Treatment of Pseudomonas Infections in Mechanically Ventilated Patients: May 19, 2008
KaloBios Expands Senior Management Team: May 5, 2008
KaloBios Completes Patient Dosing in its U.S. Phase 1 Trial of Its Third Drug Candidate, KB003: April 28, 2008
KaloBios Initiates Phase 1/2 Trial of Humaneered� Monoclonal Antibody KB001 for Treatment of Pseudomonas Infections in Cystic Fibrosis Patients: March 31, 2008
KaloBios Initiates Phase 1/2 Trial of KB002 Engineered Monoclonal Antibody in Persistent Asthma: March 10, 2008
KaloBios Strengthens Development Expertise with Additions to Senior Management Team: January 29, 2008
KaloBios Elects Denise M. Gilbert, Ph.D. to the Board of Directors: January 28, 2008
KaloBios Raises $20 Million in Series C Financing: July 23, 2007
KaloBios Initiates a U.S. Phase 1 Study of Its Second Drug Candidate, KB001: June 11, 2007
KaloBios Bolsters Development Expertise with New Chief Medical Officer and SVP, Regulatory Affairs, Quality and Project Management : June 8, 2007
KaloBios Licenses Humaneering� Technology to Major Pharmaceutical Company: April 23, 2007
KaloBios Commences Clinical Trial of Novel Antibody Rheumatoid Arthritis Drug Candidate: November 9, 2006
KaloBios Pharmaceuticals Appoints David W. Pritchard as President and Chief Executive Officer: October 12, 2006
KaloBios Collaborates to Engineer Human Antibody Therapeutic Drugs, Successful completion of first Humaneering� program and commencement of a broader agreement: June 1, 2006
KaloBios Pharmaceuticals Raises $20 Million in Private Equity, Led by MPM Capital and GBS Ventures: March 16, 2005
KaloBios In-Licenses Rheumatoid Arthritis Drug from the Ludwig Institute for Cancer Research: July 22, 2004
KaloBios Pharmaceuticals In-Licenses Antibody from UCSF to Prevent and Treat Pseudomonas Infections: June 2, 2004
KaloBios and Celscia Therapeutics Announce Merger: January 12, 2004
In Vivo Article: December 19, 2003
KaloBios Completes $4 Million in Seed Funding from Sofinnova Ventures and Alloy Ventures: June 24, 2003
copyright ©2010 KaloBios Pharmaceuticals, Inc.
